8-K filed October 21, 2024, 7:59 PM ET ticker ENGN CIK 0001980845

leadership confidence high sentiment neutral materiality 0.55

enGene announces executive changes: new CTO, CSO, and President; Sullivan separation

enGene Therapeutics Inc.

Joan Connolly appointed CTO effective Oct 21; brings 30+ yrs experience from Albireo, Stemline, Bristol-Myers.
Anthony Cheung transitions from CTO to CSO; James Sullivan departs Oct 31, 2024.
Sullivan separation agreement includes $485k salary continuation, prorated bonus, equity acceleration, option extension.
Alexander Nichols becomes Chief Strategy & Operations Officer; CEO Ron Cooper adds President title.
Detalimogene pivotal study ongoing; enGene expects BLA submission mid-2026.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Anthony Cheung

Chief Scientific Officer

ENGN · enGene Therapeutics Inc.

Effective: 2024-10-21
Filed: October 21, 2024, 7:59 PM ET

Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer

Role change

Ronald H.W. Cooper

President

ENGN · enGene Therapeutics Inc.

Effective: 2024-10-21
Filed: October 21, 2024, 7:59 PM ET

Mr. Ronald H.W. Cooper, assumed the additional title of President

Departed

James Sullivan

Chief Scientific Officer

ENGN · enGene Therapeutics Inc.

Effective: 2024-10-31
Successor: Anthony Cheung
Filed: October 21, 2024, 7:59 PM ET

Dr. Sullivan shall depart the Company effective October 31, 2024

Role change

Alexander Nichols

Chief Strategy and Operations Officer

ENGN · enGene Therapeutics Inc.

Effective: 2024-10-21
Filed: October 21, 2024, 7:59 PM ET

Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Cheung was appointed as Chief Scientific Officer at enGene Therapeutics Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald H.W. Cooper changed role as President at enGene Therapeutics Inc..

Action: assumed additional title of President
Role: President

Exact text from the filing

Mr. Ronald H.W. Cooper, assumed the additional title of President

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Sullivan departed as Chief Scientific Officer at enGene Therapeutics Inc..

Action: depart
Role: Chief Scientific Officer

Exact text from the filing

Dr. Sullivan shall depart the Company effective October 31, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Nichols was appointed as Chief Strategy and Operations Officer at enGene Therapeutics Inc..

Action: appointed
Role: Chief Strategy and Operations Officer

Exact text from the filing

Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-115767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.